Related Experiment Video
Updated: Aug 2, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Neurodevelopmental outcomes in children with HIV infection under 3 years of age
C J Foster1, R L Biggs, D Melvin
1The Family Clinic, St Mary's Hospital, Praed Street, London, UK.
Insights
Combination antiretroviral therapy improves immune function in children with human immunodeficiency virus type 1 (HIV-1). However, neurological signs and developmental delays often persist despite treatment.
Area of Science:
- Pediatric Infectious Diseases
- Neurodevelopmental Disorders
- Virology
Background:
- Children with vertically acquired human immunodeficiency virus type 1 (HIV-1) infection are surviving into adulthood due to combination antiretroviral therapy (cART).
- Long-term neurodevelopmental outcomes in this population require thorough investigation.
Purpose of the Study:
- To evaluate the neurodevelopmental outcomes in children diagnosed with HIV-1 infection before age three.
- To correlate neurological and developmental status with immunological and virological responses to cART.
Main Methods:
- Retrospective review of 62 children with vertically acquired HIV-1 infection diagnosed before age three.
- Assessment of neurological signs and standardized developmental assessments.
- Analysis of immunological (CD4 counts) and virological (viral load) data in response to cART.
Main Results:
- Twenty-two percent (14/62) of children exhibited abnormal neurological signs.
- Forty percent (25/62) demonstrated significant developmental delay.
- Children with severe HIV-1 disease and immune compromise at presentation had worse neurological and developmental outcomes.
- cART improved immune function, viral control, and growth, but neurological deficits persisted.
Conclusions:
- Despite improvements in immune status and viral suppression with cART, significant neurodevelopmental challenges remain in children with vertically acquired HIV-1.
- Early diagnosis and intervention are crucial, but long-term monitoring for neurological sequelae is essential.
Abstract:
Following the introduction of combination antiretroviral therapy, children vertically infected with the human immunodeficiency virus (HIV-1) living in the developed world are surviving into adult life. This paper reviews the neurodevelopmental outcomes of 62 consecutively-presenting children with HIV-1 infection diagnosed before 3 years of age (32 males, 30 females; median age at presentation 6 mo). Neurological and developmental data are presented with immunological and virological responses to antiretroviral therapy. Fourteen children (22%) had abnormal neurological signs and 25 (40%) demonstrated significant developmental delay on standardized developmental assessments. Children presenting with more severe HIV-1 disease and immune compromise had significantly more abnormal neurological signs and developmental delays than children presenting with milder HIV-1 symptomatology. Immune function, control of HIV-1 viral replication, and growth parameters improved with antiretroviral therapy (median age at last follow-up 7 y 3 mo); however, abnormal neurological signs and significant gross motor difficulties persisted.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Three Developmental Domains
Physical Development
Physical processes, also known as maturation, encompass the biological changes that occur across an individual's life. These changes begin with genetic inheritance and continue through various stages, including growth in height and weight,...
Cryptococcal Meningitis
Inhibitors of Virion Maturation and Assembly

